Disease mongering
6.7K views | +0 today
Follow
 
Scooped by Giuseppe Fattori
onto Disease mongering
November 1, 2017 3:46 PM
Scoop.it!

Patient advocacy groups feel pressure of corporate donors

Patient advocacy groups feel pressure of corporate donors | Disease mongering | Scoop.it

At a time when drug company lobbyists are widely vilified as icons of avarice, patient advocacy groups still wear the white hats.

But those organizations, which promote cures for every type of cancer and hundreds more diseases, have come under criticism lately for favoring their drug company funders in contests on Capitol Hill.

In one case, a diabetes group accepted money from food companies and played down the health risks from their high-sugar products; in another case, a mental health association, reliant on drug company dollars, opted to keep quiet about the soaring prices of its antidepressants. And many of the patient advocacy groups pushing for passage of the 21st Century Cures Act, which consumer groups argue rolls back patient protection, are funded in large part by pharmaceutical firms.

No comment yet.
Disease mongering
Overdiagnosis of disease: a modern epidemic sickness.
Your new post is loading...
Your new post is loading...
Scooped by Giuseppe Fattori
November 22, 2014 5:15 AM
Scoop.it!

Sandoz: un 'tariffario' per trattare pazienti con ormoni

Sandoz: un 'tariffario' per trattare pazienti con ormoni | Disease mongering | Scoop.it
C'era un sorta di tariffario per ricompensare i medici che mettevano i pazienti sotto terapia di Omnitrope un ormone della crescita biosimilare secondo quanto hanno scoperto le indagini dei Nas
No comment yet.
Scooped by Giuseppe Fattori
September 30, 5:57 AM
Scoop.it!

Promoting diseases to promote drugs: The role of the pharmaceutical industry in fostering good and bad medicalization

Promoting diseases to promote drugs: The role of the pharmaceutical industry in fostering good and bad medicalization | Disease mongering | Scoop.it

The pharmaceutical industry and drugs advertisements are sometimes accused of “creating diseases”. This article assesses and describes the role of that industry in fostering medicalization. 

No comment yet.
Scooped by Giuseppe Fattori
September 30, 5:51 AM
Scoop.it!

Disease Mongering: la promoción de enfermedades en la identidad de las personas mayores –

Disease Mongering: la promoción de enfermedades en la identidad de las personas mayores – | Disease mongering | Scoop.it
Mediante estrategias narrativas en los medios de comunicación se modulan las creencias en la sociedad con la finalidad de que el público ubique su atención en condiciones inocuas. La construcción de la vejez como un problema, un trastorno o enfermedad, deviene en elecciones condicionadas y generando mayor consumo de tecnología médica, servicios de salud y […]
No comment yet.
Scooped by Giuseppe Fattori
April 27, 2021 3:06 PM
Scoop.it!

Inventori di malattie: il dottor Knock e il trionfo della medicina

C'era una volta Il giornalista Silvestro Montanaro, conduttore del programma RAI "C'era una volta", racconta di come l'industria farmaceutica "crea" le malattie. 

No comment yet.
Scooped by Giuseppe Fattori
September 3, 2019 11:12 AM
Scoop.it!

FDA Depends on Industry Funding; Money Comes with “Strings Attached”

FDA Depends on Industry Funding; Money Comes with “Strings Attached” | Disease mongering | Scoop.it
The Food and Drug Administration depends on the drug industry for much of its funding, and that money, in the form of “user fees,” comes with strings attached: every five years, the pharmaceutical industry gets to negotiate with the FDA the terms under which funding i
No comment yet.
Scooped by Giuseppe Fattori
February 20, 2019 5:49 PM
Scoop.it!

Instagram influencers are selling you drugs and medical devices - #DiseaseMongering

Instagram influencers are selling you drugs and medical devices - #DiseaseMongering | Disease mongering | Scoop.it
Big pharma is partnering with influencers to sell new drugs and medical devices.

Using influencers to sell products to the sick can be a particularly insidious form of marketing in large part because of the vague parameters set by the FTC and FDA. With today’s ambiguous regulations, health care sponcon will continue to saturate our feeds with posts that appear sincere but end up being misleading. Consumers looking for remedies to what ails them should not be expected to differentiate nuances in regulatory wording between “clinically validated” and “FDA-approved.”

No comment yet.
Scooped by Giuseppe Fattori
October 1, 2018 2:30 PM
Scoop.it!

Caso Cochrane: il bambino e l'acqua sporca

Caso Cochrane: il bambino e l'acqua sporca | Disease mongering | Scoop.it
La proposta di espulsione dall’organo di governo della Cochrane di Peter Gøtzsche continua ad agitare le acque della associazione internazionale dedicata a produrre “informazioni di alta qualità per le decisioni di salute”.
No comment yet.
Scooped by Giuseppe Fattori
October 1, 2018 11:38 AM
Scoop.it!

Tra informazione e fiducia, la scienza di fronte al caso Cochrane

Tra informazione e fiducia, la scienza di fronte al caso Cochrane | Disease mongering | Scoop.it
C’è una tempesta, anzi, un uragano, che sta travolgendo il mondo della ricerca biomedica, all’insaputa del grande pubblico, quasi fosse qualcosa che interessa solo pochi addetti ai lavori. Ne ha accennato il Manifesto, ne ha riferito Wired, ma per il resto, sui grandi mezzi di comunicazione, nemmeno una parola. In apparenza, d’altra parte, quella di questi giorni sembra una vicenda banale.
No comment yet.
Rescooped by Giuseppe Fattori from Useful AOD Reports & Resources
June 22, 2018 3:26 AM
Scoop.it!

Alcohol industry involvement in science: A systematic review of the perspectives of the alcohol research community 

Alcohol industry involvement in science: A systematic review of the perspectives of the alcohol research community  | Disease mongering | Scoop.it

Issues

Alcohol companies have recently invested large sums of money in answering research questions to which they have clear vested interests in the outcomes. There have been extensive concerns about corporate influence on public health sciences, following the experience with the tobacco industry.

Approach

This systematic review aims to investigate the perspectives of researchers on the activities of alcohol industry actors in relation to science, in order to guide future research. All data published in peer‐reviewed journals (including commentaries, opinion pieces, editorials and letters as well as research reports) were eligible for inclusion. This analysis focuses on the manifest rather than latent content of the articulated views, and accordingly adopts a thematic analysis using an inductive approach to the generation of themes.

Key Findings

There are serious concerns identified in three main areas, principally defined by where the impacts of industry scientific activities occur; on evidence informed policy making (instrumental uses of research by industry actors), on the content of the scientific evidence base itself (industry funding as a source of bias); and on the processes of undertaking research (transgressions of basic scientific norms). There are also opposing views which provide a useful critique. The evidence‐base on the validity of all concerns has been slow to develop.


Via ReGenUC
No comment yet.
Rescooped by Giuseppe Fattori from Pharma Industry Regulation
November 15, 2017 2:48 PM
Scoop.it!

93% of “Patient Advocacy Groups” Included in #FDA Funding Discussions Receive $ from #Pharma

93% of “Patient Advocacy Groups” Included in #FDA Funding Discussions Receive $ from #Pharma | Disease mongering | Scoop.it

 

“Patient advocacy” groups have a unique power on Capitol Hill. They claim to represent the true voice of constituents, untainted by special interest bias. Politicians and the Food and Drug Administration use their endorsements as reflective of genuine public support.

 

But a new study shows that nearly all of these patient advocacy groups are captured by the drug industry.

 

David Hilzenrath at the Project on Government Oversight (POGO) reports that at least 39 of 42 patient advocacy groups who participated in discussions with the FDA over agency review processes for prescription drugs received funding from pharmaceutical companies. And at least 15 have representatives of drug or biotechnology companies on their governing boards.

 

The study is particularly notable now because Congress is poised to pass the 21st Century Cures Act, which trades temporary additional funding for the National Institutes of Health and the FDA for permanent weakening of the FDA’s approval process. Over 1,400 lobbyists have been working on this bill, which would be a major financial boon to the drug and medical device industries.

 

Patient advocacy groups have factored heavily into the lobbying effort. According to an analysis from research group Avalere in December 2014, 43 percent of public comments on the House version of the bill were from patient advocacy groups.

 

But those groups are not necessarily independent, POGO warns.

 

For instance, the National Health Council, a group that calls itself “The United Patient Voice” and has advocated before the FDA for faster drug approvals, includes on its board of directors leaders of the two main trade groups for the drug industry — Pharmaceutical Research and Manufacturers of America (PhRMA), and Biotechnology Innovation Organization (BIO) – along with executives from drug companies Sanofi, Johnson & Johnson, and Alkermes. PhRMA gave the National Health Council $1.2 million in 2014; in all, 77 percent of its funding came from the pharmaceutical and biotech industries, according to POGO. Its “Policy Action Team” also has a PhMRA representative on it, along with an employee of Johnson & Johnson.

 

Further Reading:


Via Pharma Guy
No comment yet.
Scooped by Giuseppe Fattori
October 21, 2017 3:45 PM
Scoop.it!

PHARMA-FREE ADVOCACY GROUPS: the list of health advocacy and consumer groups that take no funding from pharmaceutical

PHARMA-FREE ADVOCACY GROUPS: the list of health advocacy and consumer groups that take no funding from pharmaceutical | Disease mongering | Scoop.it

This is a list of health advocacy and consumer groups in the U.S. and Canada that take no funding from pharmaceutical, medical device, or biotech companies. The voices of independent groups that truly represent patients and consumers are drowned out by the thousands of groups that take money from industry and push industry viewpoints – or stay silent on drug safety, drug costs, and other issues vital to patients. This list is meant to be a resource for media and consumers who want to listen to – and support – independent groups whose opinions are not swayed by industry.

To learn more about pharma-funded advocacy groups, please read some of our articles on how pharma-funded groups negatively affect healthcare. For an in-depth analysis of the effect of industry funding of breast cancer groups, check out Health Advocacy, Inc.

Want to be on the list? If you represent a patient or consumer health advocacy group that does not take money from manufacturers of drugs, medical devices, biologics, or diagnostics, please email us at pharmedout@gmail.com with a link to your organization's website, 3 years worth of 990s (or t1004 or t3020 for Canadian groups) and annual reports, and a statement that the organization does not take money from industry and has a policy not to take money from industry. The groups submitted will be vetted by a committee that includes Sharon Batt PhD, author of Health Advocacy, Inc. and Adriane Fugh-Berman MD, director of PharmedOut.

No comment yet.
Scooped by Giuseppe Fattori
September 24, 2017 12:13 PM
Scoop.it!

Can Pharma Influence Physician Prescribing? The median amount of prescribed drugs was exactly the same between those doctors who received money from the pharmaceutical companies and those that did ...

Can Pharma Influence Physician Prescribing? The median amount of prescribed drugs was exactly the same between those doctors who received money from the pharmaceutical companies and those that did ... | Disease mongering | Scoop.it
Can Pharmaceuticals Buy Doctor's Prescription Pads? Its a complicated topic but new evidence suggests it might be harder than reported in the past. Using prostate cancer drugs these investigators did not find pharmaceutical payments impact doctor's habits at all.

 

The short answer is we found very little correlation between payments given to physicians and the amount of drug they dispense.  In fact, the median amount of prescribed drugs was exactly the same between those doctors who received money from the pharmaceutical companies and those that did not.  You can read the paper to get a feel for some of the other nuances of our findings but suffice it to say no strong relationship was seen.  Within this narrow spectrum of prostate cancer drugs, pharma payments did not seem to make a difference at all to the prescribing habits of doctors.

 

No comment yet.
Scooped by Giuseppe Fattori
November 13, 2015 4:19 AM
Scoop.it!

Wary of conflicts, universities taking less money from drug companies

Wary of conflicts, universities taking less money from drug companies | Disease mongering | Scoop.it

Facing state budget cuts to the University of Wisconsin system and dwindling federal funding, Robert Golden would love to find a pile of money somewhere.

But there are certain things Golden — and some other medical school officials across the country — say they won't do: take money from drug companies for doctor education programs and let them have any say in what goes into the courses.


No comment yet.
Scooped by Giuseppe Fattori
December 12, 2023 12:39 PM
Scoop.it!

Big Pharma Invented These Diseases To Sell Drugs (Osteoporosis Is One Of Them)

Big Pharma Invented These Diseases To Sell Drugs (Osteoporosis Is One Of Them) | Disease mongering | Scoop.it

Uno dei primi esempi di diffusione di malattie è la Listerine, inventata nel 1879 e utilizzata come antisettico e persino come detergente per pavimenti prima che i suoi creatori capissero come venderla. Dopo averlo commercializzato ai dentisti per l'igiene orale in studio, hanno iniziato a venderlo direttamente ai consumatori. Solo che i consumatori non ne avevano bisogno. Così i creatori hanno inventato una malattia che il loro prodotto “cura”: l’alitosi, che non è altro che l’alitosi.

No comment yet.
Scooped by Giuseppe Fattori
September 30, 5:52 AM
Scoop.it!

Disease mongering, overdiagnosis, and media practices: a critical discourse analysis of sluggish cognitive tempo (SCT) and the motivational deficiency disorder (MoDeD) spoof

Disease mongering, overdiagnosis, and media practices: a critical discourse analysis of sluggish cognitive tempo (SCT) and the motivational deficiency disorder (MoDeD) spoof | Disease mongering | Scoop.it

This paper explores ways in which the strategic use of discursive and generic conventions has the potential to create a non-existent pathology and mislead the public. 

No comment yet.
Scooped by Giuseppe Fattori
December 12, 2023 12:36 PM
Scoop.it!

Il commercio di malattie

Il commercio di malattie | Disease mongering | Scoop.it

Il disease mongering (commercio di malattie) è una forma di medicalizzazione che provoca l’aumento del numero di malattie e malati allo scopo di allargare il mercato della salute. Tale commercio viene esteso alle problematiche della vita e della morte, alle emozioni, alla sessualità.

No comment yet.
Rescooped by Giuseppe Fattori from Italian Social Marketing Association - Newsletter 220
September 18, 2019 6:15 PM
Scoop.it!

Non, le thé vert ne protège pas du cancer

Non, le thé vert ne protège pas du cancer | Disease mongering | Scoop.it
Le thé vert est loué pour ses bienfaits supposés sur la santé, voire pour prévenir le cancer. Mais aucune étude ne permet de montrer de telles propriétés.Le thé est la deuxième boisson la plus consommée dans le monde, après l'eau. Dans certains pays, sa consommation est un art de vivre faisant l'objet d'un cérémonial très codifié.Devenue un produit tendance chez les jeunes, cette boisson fait désormais l'objet d'une intense promotion de ses bienfaits présumés pour la santé et le bien-être (promesses de propriétés « détox », de drainage, etc.). Dans le cas du thé vert, de supposées propriétés « anticancer » sont également mises en avant. Qu'en est-il réellement ?

 

 

No comment yet.
Scooped by Giuseppe Fattori
May 8, 2019 5:33 AM
Scoop.it!

The Birth-Tissue Profiteers — Caroline Chen

The Birth-Tissue Profiteers — Caroline Chen | Disease mongering | Scoop.it
How well-meaning donations end up fueling an unproven, virtually unregulated $2 billion stem cell industry.
No comment yet.
Rescooped by Giuseppe Fattori from PATIENT EMPOWERMENT & E-PATIENT
November 28, 2018 3:22 PM
Scoop.it!

5,4 millions d'incidents en dix ans aux Etas-Unis. « Implants Files » : les 10 implants qui ont causé le plus d’incidents

5,4 millions d'incidents en dix ans aux Etas-Unis. « Implants Files » : les 10 implants qui ont causé le plus d’incidents | Disease mongering | Scoop.it
Infographie. Le Consortium international des journalistes d’investigation (ICIJ) a constitué une base de données des incidents survenus entre 2009 et 2017 aux Etats-Unis : en tête, les pompes à insuline.

Via Lionel Reichardt / le Pharmageek
No comment yet.
Scooped by Giuseppe Fattori
October 1, 2018 11:47 AM
Scoop.it!

Cochrane: la attende uno scisma? | DottProf

Cochrane: la attende uno scisma? | DottProf | Disease mongering | Scoop.it

Le revisioni sistematiche di alta qualità sono fondamentali per prendere decisioni basate sulle prove e “nessuna organizzazione ha contribuito alla loro produzione come ha fatto la Cochrane, in precedenza Cochrane Collaboration,ora al suo 25° anno.” La breve nota del direttore del BMJ, Fiona Godlee, si aggiunge al confronto di questi giorni.  Vale la pena fare attenzione ai dettagli della sua Editor’s Choice

.We must hope that Cochrane remembers its roots. Fiona Godlee

 

No comment yet.
Rescooped by Giuseppe Fattori from Public Health - Santé Publique
September 25, 2018 3:12 PM
Scoop.it!

Why modern medicine is a major threat to public health 

Why modern medicine is a major threat to public health  | Disease mongering | Scoop.it
Most patients will derive no health improvement from medication. We should tackle the root causes of disease instead

When former airline pilot Tony Royle came to see me last year to seek reassurance that it was OK to participate in an Ironman event, having stopped all his medications 18 months after suffering a heart attack, I was initially a little alarmed.

But after talking to him, I realised he had made an informed decision to stop the medication after suffering side effects, and instead had opted for a diet and lifestyle approach to manage his heart disease.

His case is a great example of how evidence-based medicine should be practised. This is the integration of clinical expertise, the best available evidence and – most importantly – taking patients’ preferences and values into consideration.


Via Lionel Reichardt / le Pharmageek
No comment yet.
Scooped by Giuseppe Fattori
May 12, 2018 2:49 PM
Scoop.it!

I dati sul cancro svenduti alle società farmaceutiche

I dati sul cancro svenduti alle società farmaceutiche | Disease mongering | Scoop.it
“Lo sponsor non ha avuto alcun ruolo nella conduzione dello studio e nella scrittura del lavoro”. Ma dietro questa dicitura, riportata nel Rapporto sulla sopravvivenza dei pazienti oncologici in Italia pubblicato nel 2017 dall’Associazione italiana registri tumori (Airtum), c’è ben altro. Dati venduti dal Registro Tumori a una multinazionale del farmaco, la Msd, interessata ad …
No comment yet.
Scooped by Giuseppe Fattori
November 1, 2017 3:46 PM
Scoop.it!

Patient advocacy groups feel pressure of corporate donors

Patient advocacy groups feel pressure of corporate donors | Disease mongering | Scoop.it

At a time when drug company lobbyists are widely vilified as icons of avarice, patient advocacy groups still wear the white hats.

But those organizations, which promote cures for every type of cancer and hundreds more diseases, have come under criticism lately for favoring their drug company funders in contests on Capitol Hill.

In one case, a diabetes group accepted money from food companies and played down the health risks from their high-sugar products; in another case, a mental health association, reliant on drug company dollars, opted to keep quiet about the soaring prices of its antidepressants. And many of the patient advocacy groups pushing for passage of the 21st Century Cures Act, which consumer groups argue rolls back patient protection, are funded in large part by pharmaceutical firms.

No comment yet.
Rescooped by Giuseppe Fattori from Co-creation in health
October 21, 2017 3:25 PM
Scoop.it!

Very Few Patient Groups Don’t Take Pharma Money

Very Few Patient Groups Don’t Take Pharma Money | Disease mongering | Scoop.it

Most patient and consumer advocacy groups receive funds from the pharmaceutical industry, according to a new study released by the group PharmedOut.

 

Only a handful out of 7,685 health advocacy groups in the U.S. are completely independent of pharmaceutical industry money, according to a list the group released Oct. 13. PharmedOut is a Georgetown University Medical Center project that advances evidence-based prescribing and educates health-care professionals about pharmaceutical marketing practices.

 

And industry funding of patient groups, including websites and informational materials, is often not apparent to the average consumer, which could mislead consumers into believing they’re getting unbiased health advice.

 

“Industry funding is often not disclosed on websites or informational materials or is hidden,” PharmedOut Director Adriane Fugh-Berman told me in an Oct. 16 phone call. Funding and sponsorship is often very subtle and difficult to identify, she said.

 

In addition, she said, industry sponsorship can affect the stands patient and consumer groups are willing to take, she said.

 

Groups that accept industry funding are affected by that money, regardless of whether they think they are, she said.

 

"Look at the stands taken and not taken,” she said. “For example, where is the anger and outrage about drug costs?”

 

Fugh-Berman is an associate professor in the Department of Pharmacology and Physiology and in the Department of Family Medicine at Georgetown University Medical Center.

 

Further Reading:

  • “Pharma 'Patient Centricity' Aids & Abets the Opioid Epidemic”; http://sco.lt/5RJse1

  •  “93% of Patient Advocacy Groups Included in FDA Funding Discussions Receive $ from Pharma”; http://sco.lt/8jkvFh

  • “Patient Advocacy Groups with Funding & Form Letter from @PhRMA Oppose Nevada Legislation”; http://sco.lt/6QlP9N
  • “More Than Two-thirds of Patient Advocacy Groups Receive Industry Funding”; http://sco.lt/6Ftgzh

Via Pharma Guy, Giuseppe Fattori
No comment yet.
Rescooped by Giuseppe Fattori from Social Media and Healthcare
September 1, 2017 1:20 AM
Scoop.it!

Big Pharma and Social Media: How to Avoid Trouble with the FDA

Big Pharma and Social Media: How to Avoid Trouble with the FDA | Disease mongering | Scoop.it

Pharmaceutical companies can use social media to engage and educate patients as well as to provide reliable information about their products. But how do companies tap social media without running afoul of the Food and Drug Administration (FDA) and various regulatory requirements? To find out, I asked Colleen Tracy James, a partner in Mayer Brown’s New York office, where she is a member of the firm’s intellectual property practice and life sciences group.

Belbey: What are the challenges facing pharmaceutical firms when using social media?

James: The internet is the wild wild West. We are still figuring out how to maneuver and make sure information is reliable and trustworthy. This is especially important when it comes to pharmaceutical products because it impacts our health and well-being. Pharmaceutical companies face a lot of challenges on social media, such as how to handle incomplete and misinformation about their products. We all remember the famous Kim Kardashian Instagram post where she touted the benefit of a drug that treats morning sickness, but she did not disclose any of the side effects. According to the FDA Guidance, when you use social media, you need to include the ‘good, bad and the ugly' about your product. Your social media posts need to be fair and balanced.

Belbey: How can pharmaceutical companies control the message and the information?

James: One way to control the message is to create what the industry calls a “controlled environment” such as creating a company webpage for a drug or disease. In this way, firms can make sure information is accurate and complete. That keeps them in line with the FDA regulations. That’s very different from third party information, where the company does not have control over how its product are discussed.

Belbey: Can firms use controlled environments and social media to correct misinformation?

James: Yes. If patients are talking to each other and sharing a misconception of your product, you may want to, as a company, respond to that. You may decide to allow certain employees in the corporation to engage with potential consumers on social media and to answer questions. Or you could provide a chat room as part of your own platform. In that case, your obligation to correct misinformation may be heightened because now you have control of that website.

Belbey: How can pharmaceutical firms use Twitter?

James: Twitter is one of the areas where we’ve seen some specific guidance from the FDA. Due to its character limitations, the FDA is concerned that if you don’t have enough space, you can’t provide a fair and balanced (benefits and downsides) view of your drug. Pharmaceutical companies face serious penalties by the FDA if they don’t make the proper disclosures --  something that pharmaceutical companies want to avoid. If you are responsible for disseminating misinformation about your drug, and the wrong person takes it because he or she wasn’t aware of the contraindications or the side effects, the pharmaceutical companies open themselves up for liability. In short, pharmaceutical companies must be careful not to mislead consumers on Twitter.

Belbey: Given that there are real risks associated with not complying with advertising rules and regulations, how should firms move forward safely?

James: Pharmaceutical firms should develop clear and decisive social media advertising policies. First, they need to figure out which platforms they will use, how they will control their messages, whether they’re going to allow chat rooms, and how to manage comments from patients who want a dialog. If interactivity is permitted, companies need to clearly define which employees may interact with consumers, patients and doctors on social media.

The firm also needs a content strategy, so that responses are in compliance with what the FDA has approved the pharmaceutical company may say about their product. You also may need a team of legal advisers to confirm that content about your product is okay to put on social media. Pharmaceutical companies must be careful that employees don’t provide people with wrong information when responding on social media. For example, you can’t say, “This medication is for a headache but you can also take it for something else that’s not a headache.” That would be a violation, historically speaking, as firms are not allowed to market their drugs’ off-label uses or mention off-label uses. And finally, I also suggest that companies have a compliance officer tasked with making sure there’s a policy in place and it’s being complied with and updated with evolving FDA guidance.

Since the FDA was created, we’ve gone from radio to TV and to now social media. Just like the past when industry adapted to new forms of communications, pharmaceutical companies are now figuring out how to advertise and communicate using the latest media within the regulatory framework.

Contributor’s notes: For more information, read “5 Social Media Pitfalls In The Pharmaceutical Industry” by Henniger Bullock and Colleen Tracy James, Mayer Brown LLP. https://www.mayerbrown.com/files/News/29b609ec-4b5a-4ce3-950c-04026ef73f85/Presentation/NewsAttachment/39dca070-2b87-49a6-b03a-04e8e6f9bafc/5SocialMediaPitfallsInThePharmaceuticalIndustry.pdf

Here is guidance from the FDA pertaining to advertising and social media for your convenience:

Medical Product Communications That Are Consistent With the FDA-Required Labeling — Questions and Answers (Draft Jan 2017): https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM537130.pdf

Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities – Questions and Answers (Draft 2017): https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM537347.pdf

FDA Draft Guidance for Industry Internet/Social Media Platforms with Character Space Limitations – Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices (June 2014): https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm401079.pdf

FDA Draft Guidance for Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices (June 2014): https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm401079.pdf

Fulfilling Regulatory Requirements for Postmarking Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics (Draft Jan 2014): https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm381352.pdf

Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices (December 2011): https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm285145.pdf

This blog appeared previously on Forbes.


Via Plus91
No comment yet.
Scooped by Giuseppe Fattori
March 30, 2017 5:49 AM
Scoop.it!

Il medico spezzagambe e la bella vita. I viaggi extralusso, le pretese oscene

Il medico spezzagambe e la bella vita. I viaggi extralusso, le pretese oscene | Disease mongering | Scoop.it
Amava viaggiare comodo e non certo a spese proprio il primario di ortopedia del Gaetano Pini di Milano, Noberto Confalonieri, da tre giorni agli arresti domiciliari per corruzione, turbativa d'asta e lesioni. Il medico era stato beccato in un'intercettazione mentre raccontava di "aver provocato la rottura del femore di un'anziana paziente di 78 anni, operata a suo dire per allenarsi con la tecnica" richiesta per impiantare protesti di due grandi aziende produttrici di materiale ortopedico.
No comment yet.